InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Plasma Fractionation Market Size is valued at USD 4.2 Bn in 2023 and is predicted to reach USD 8.9 Bn by the year 2031 at a 10.1 % CAGR during the forecast period for 2024-2031.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2140
Fractionation is the process of isolating specific components from a mixture. In the medical field, plasma—the liquid portion of blood—is fractionated to obtain essential derivatives such as albumin and immunoglobulins. These plasma-derived products possess significant therapeutic properties and are widely used in the treatment of various blood plasma-related disorders.
The growing global elderly population, which is more susceptible to rare diseases requiring plasma derivatives, is a key factor driving the expansion of the plasma fractionation market. Additionally, the increasing utilization of immunoglobulins and alpha-1-antitrypsin across various medical applications is contributing to market growth. The rising number of plasma collection centers worldwide further supports this expansion. Moreover, proactive government initiatives aimed at increasing awareness regarding the benefits of plasma-derived therapies are fostering market development.
Prominent Players in the Plasma Fractionation Market:
- CSL (Australia)
- Takeda Pharmaceutical Company Limited (Japan)
- Grifols, S.A. (Spain)
- Octapharma AG (Switzerland)
- Kedrion S.P.A (Italy)
- LFB (France)
- ADMA Biologics (US)
- Sanquin (Netherlands)
- China Biologic Products Holdings Inc. (China)
- GC Pharma (Korea)
- Hualan Bioengineering Co., Ltd. (China)
- Japan Blood Products Organization (Japan)
- Emergent BioSolutions (US)
- Shanghai Raas Blood Products Co., Ltd. (China)
- Intas Pharmaceuticals Ltd. (India)
- Bharat Serum Vaccines Limited (India)
- SK Plasma (Korea)
- Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
- Kamada (Israel)
- Centurion Pharma (Istanbul)
- Prothya Biosolutions (Netherlands)
- PlasmaGen BioSciences Pvt. Ltd. (India)
- Virchow Biotech Private Limited (India)
- Fusion Healthcare (India)
- Hemarus Therapeutics Limited
Market Dynamics:
Drivers-
The increasing prevalence of immunodeficiency disorders is a significant factor driving the expansion of the plasma fractionation market. The global demand for plasma-derived therapies has risen substantially, particularly for immunoglobulins, contributing to favorable market growth. In response to this surge in demand, leading industry players have intensified their research and development efforts to introduce innovative plasma-derived treatments. Additionally, these key market participants are strategically investing in acquiring and establishing new plasma collection centers to enhance the availability of plasma for the development of novel products.
Curious about this latest version of the report? Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2140
Challenges:
The growing adoption of recombinant therapies as an alternative to plasma-derived medicines poses a challenge to market expansion. In recent years, numerous recombinant products have been developed as substitutes for plasma-derived treatments. These recombinant alternatives are widely used in prophylactic applications and are generally less immunogenic. Additionally, advancements in long-acting replacement therapies offer significant benefits, such as reduced frequency of administration and improved efficacy in preventive care.
Regional Trends:
The Asia-Pacific region is anticipated to secure a significant market share in the plasma fractionation industry, with strong revenue growth and a high compound annual growth rate (CAGR) projected for the near future. Several factors contribute to this growth, including the presence of major companies specializing in the development and commercialization of technologically advanced plasma-derived therapies. Additionally, North America is expected to witness rapid expansion in the coming years, driven by the presence of a large number of plasma fractionation centers, particularly in the United States, which plays a crucial role in supporting market growth.
Recent Developments:
- In March 2023, Takeda made an investment of 100 billion JPY in the establishment of a novel manufacturing facility in Japan, specifically dedicated to the production of plasma-derived medicines. The investment made by Takeda exemplified the company’s dedication to prioritising patients and fulfilling its obligations in relation to its patient-centric, people-oriented, and environmentally conscious objectives. This approach was supported by the utilisation of data and digital technologies.
- In Dec 2022, CSL has recently inaugurated its Plasma Fractionation Facility in Victoria, Australia, which represents a significant milestone in the country’s plasma manufacturing sector. With a staggering investment of $900 Bn, this state-of-the-art facility stands as the largest of its type in the Southern Hemisphere. The aforementioned statement pertains to a capital investment programme of over $2 billion that CSL is presently implementing in Australia.
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/2140
Segmentation of Plasma Fractionation Market-
By Product-
- Immune-Globulins
- Intravenous Immune-Globulins
- Subcutaneous Immune-Globulins
- Other Immune-Globulins
- Coagulation Factor Concentrates
- Factor VIII
- Factor IX
- Von Willebrand Factor
- Prothrombin Complex Concentrate
- Fibrinogen Concentrates
- Factor XIII
- Others
- Albumin
- Protease Inhibitors
- Other Plasma Products
By Application-
- Neurology
- Immunology
- Hematology
- Critical Care
- Pulmonology
- Hemato-Oncology
- Rheumatology
- Others
By End-User-
- Hospitals & Clinics
- Clinical Research Laboratories
- Academic Institutes
By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Get More Information: @
https://www.insightaceanalytic.com/report/plasma-fractionation-market/2140
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
